Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Little Green Pharma Ltd. ( (AU:LGP) ) just unveiled an announcement.
Little Green Pharma Ltd. reported a significant revenue growth of over 40% for the fiscal year 2025, reaching $36.6 million, with a notable contribution from the recently acquired Health House. The company also achieved a record monthly revenue in March and saw an increase in cash receipts. The successful integration of Health House, along with the extension of NAB loan facilities and new board appointments, positions LGP for further growth. Additionally, the submission of French national cannabis legislation to the European Commission and the publication of long-term efficacy results of LGP’s medicinal cannabis indicate potential future market expansion and increased stakeholder confidence.
More about Little Green Pharma Ltd.
Little Green Pharma Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of medicinal cannabis products. The company is listed on the Australian Securities Exchange (ASX) and has recently expanded its market presence through the acquisition of Health House, a distribution business.
YTD Price Performance: -8.33%
Average Trading Volume: 139,617
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$33.37M
See more insights into LGP stock on TipRanks’ Stock Analysis page.